VIDEO: Vaccine appears promising in ovarian cancer
Click Here to Manage Email Alerts
In this video, Robert Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research, spoke with Healio about research that demonstrated the potential of a novel vaccine as front-line maintenance therapy in advanced-stage ovarian cancer.
Specifically, the vaccine — gemogenovatucel-T (Gradalis Inc.) — was well-tolerated and showed clinical benefit in patients with BRCA wild-type and homologous recombination-proficient ovarian cancer who had a complete response to primary induction therapy. The phase 2b study results were presented at the ASCO Annual Meeting.
“It is quite an interesting product because it actually has bifunctional plasmid-expressing product that produces GMCSF and also works on a T-cell activation strategy in a unique way,” Coleman said.
Although this study is not definitive, he noted, it does allow further investigation of a novel vaccine in a phase 3 study.
“Again, hope is on the horizon for immunotherapy, which has been a very difficult modality to incorporate into ovarian cancer patients,” Coleman said.
Collapse
Rocconi RP, et al. Abstract 5502. Presented at: Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Read more about
Click Here to Manage Email Alerts